BioRestorative Therapies has been granted a license to process mesenchymal stem cells, making it the first facility in New York State to be licensed for this purpose. This license allows the company to explore contract manufacturing for other regenerative medicine companies, potentially providing new revenue streams and offsetting clinical development costs. The company's stock price is likely to be positively impacted by this news in the short term.